iBio (NYSEAMERICAN:IBIO) Stock Crosses Above Fifty Day Moving Average of $0.00

iBio, Inc. (NYSEAMERICAN:IBIO – Get Rating) crossed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $0.00 and traded as high as $0.92. iBio shares last traded at $0.86, with a volume of 272,614 shares.

Wall Street Analysts Forecast Growth

Separately, JMP Securities downgraded shares of iBio from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 15th.

iBio Trading Down 4.8 %

The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.22 and a current ratio of 1.22.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in iBio by 7.5% in the third quarter. Vanguard Group Inc. now owns 11,884,917 shares of the biotechnology company’s stock valued at $2,024,000 after acquiring an additional 829,836 shares during the last quarter. BlackRock Inc. boosted its stake in iBio by 71.7% in the third quarter. BlackRock Inc. now owns 6,799,636 shares of the biotechnology company’s stock valued at $1,158,000 after acquiring an additional 2,838,918 shares during the last quarter. Millennium Management LLC purchased a new position in iBio in the second quarter valued at about $1,219,000. Renaissance Technologies LLC boosted its stake in iBio by 11.9% in the third quarter. Renaissance Technologies LLC now owns 1,287,827 shares of the biotechnology company’s stock valued at $219,000 after acquiring an additional 136,450 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in iBio by 10.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 586,227 shares of the biotechnology company’s stock valued at $252,000 after acquiring an additional 54,084 shares during the last quarter.

iBio Company Profile

(Get Rating)

iBio, Inc is a biotechnology company, which engages in the development and manufacture of biotherapeutics. It operates through the Biopharmaceuticals and Bioprocessing segments. The Biopharmaceuticals segment involves molecule discovery, development, and licensing activities. The Bioprocessing segment includes contract development and manufacturing services for recombinant proteins.